Know Cancer

forgot password

Cyclophosphamide Plus Cyclosporine in Treatment-Na ve Severe Aplastic Anemia

Phase 1/Phase 2
2 Years
Open (Enrolling)
Aplastic Anemia, Neutropenia, Pancytopenia, Severe Aplastic Anemia

Thank you

Trial Information

Cyclophosphamide Plus Cyclosporine in Treatment-Na ve Severe Aplastic Anemia

Severe aplastic anemia (SAA) is a life-threatening bone marrow failure disorder
characterized by pancytopenia and a hypocellular bone marrow. Allogeneic hematopoietic stem
cell transplantation (HSCT) offers the opportunity for cure in 70 percent of patients, but
most patients are not suitable candidates for this treatment modality due to advanced age,
comorbidities or lack of a histocompatible donor. For these patients, comparable long-term
survival is attainable with immunosuppressive treatment (IST) with anti-thymocyte globulin
(ATG) and cyclosporine (CsA). However, approximately 1/3 of patients do not show blood count
improvement after ATG/CsA and are considered to have refractory disease. Furthermore,
analysis of our own extensive clinical data suggests that poor blood count responses to a
single course of ATG (non-robust responders), even when transfusion-independence is
achieved, predicts a markedly worse prognosis compared to those who achieve a robust
hematologic improvement (protocol 90-H-0146).

The current limitations of IST in SAA are: 1) the majority of the responses observed
following initial h-ATG/CsA are partial with only a few patients achieving normal blood
counts; 2) 1/3 of patients are refractory to initial h-ATG/CsA; 3) hematologic relapses
occur in 35 percent of responders following initial response to h-ATG/CsA; 4) among relapsed
patients chronic use of CsA is not infrequent which often leads to toxicities from the long
term exposure to this drug (especially in older patients); 5) and clonal evolution is still
observed in 10-15 percent of patients. Efforts to improve initial IST in treatment-na ve
patients with the addition of mycophenolate mofetil and sirolimus to standard h-ATG/CsA or
use of lymphocytotoxic agents such as r-ATG/CsA or alemtuzumab have not yielded the expected
better outcomes when compared to standard h-ATG/CsA (protocols 00-H-0032, 03-H-0193, and
06-H-0034). Because the majority of SAA patients in the US and worldwide are treated with
IST due to lack of an HLA-matched donor or inaccessibility to transplant, novel regimens are
needed to overcome the current limitations of IST in SAA. Towards the goal of addressing
these limitations we are proposing a regimen of cyclophosphamide (Cy) plus low dose CsA.

Cy has been proposed by the investigators at Johns Hopkins as an alternative IST regimen to
h-ATG/CsA. In a pilot study, high dose Cy (200 mg/kg) yielded similar results to that
observed for h-ATG/CsA. In a randomized study at NHLBI comparing high dose Cy (200 mg/kg)
and h-ATG/CsA in treatment-na ve patients (protocol 97-H-0117), excess toxicity and deaths
from invasive fungal infections were observed in the Cy arm which led to the discontinuation
of this regimen. Recently reported long-term results from Johns Hopkins of 44 treatment-na
ve patients who received high dose Cy (200 mg/kg) as sole therapy for SAA showed that a
greater number of complete responses were observed with few instances of relapse and clonal
evolution noted with Cy when compared to h-ATG/CsA (historical comparison). In an
accompanying editorial, the incidence of invasive fungal infections in this cohort were
highlighted. Of note, antifungal prophylaxis against Aspergillus sp, the deadliest culprit
when neutropenia is severe and prolonged, was not employed in the Hopkins high dose Cy
protocol. In the Chinese experience, data presented in a recent meeting in Japan showed that
lower doses of Cy (120 mg/kg) plus CsA achieved similar results reported by the Hopkins
investigators with reduced toxicity. These data suggest that Cy has activity in SAA and
could be a viable alternative to standard h-ATG/CsA if the immediate toxicities associated
to prolonged neutropenia could be overcome.

In recent years we have observed a marked improvement in survival in our SAA patients
especially among those who are non-responders to IST where pancytopenia remain persistent
for months. A detailed analysis (shown in Section 2.4 Scientific and Clinical Justification
of Protocol) showed that better antifungal supportive care in recent years contributed to a
reduction of infection-related mortality in the months following IST among non-responders,
who remain persistently neutropenic. This observation suggests that nowadays patients can be
better supported through periods of neutropenia due to improved antifungal supportive care
with agents that are better tolerated (compared to deoxycholate amphotericin B), retain a
broad-spectrum of activity (especially against Aspergillus sp), and can be administered
orally as an outpatient.

The fact that about one-thirdof initial refractory patients respond to retreatment and that
late complications (relapse and clonal evolution) occur in about 40-50 percent of cases
suggest that initial IST with h-ATG/CsA has important limitations. Therefore, we propose to
investigate Cy + CsA as initial therapy in SAA. Our intention is not to recapitulate the
high dose Cy regimen initially proposed by Hopkins (200 mg/kg) but instead, investigate
lower doses proposed by the Chinese (120 mg/kg) in addition to low dose CsA (target
therapeutic level 100 - 200 microg/L). The ability to better support patients during periods
of neutropenia with better antifungals should allow for the immediate toxicity to be
overcome and assess the activity of Cy in SAA.

The main objective of this study is to assess the safety and efficacy of Cy 120 mg/kg + low
dose CsA (100 - 200 microg/L) in treatment-naive SAA. The primary endpoint will be
hematologic response, defined as no longer meeting criteria for SAA, at 6 months. Secondary
endpoints are relapse, robustness of hematologic recovery at 6 months, response at 3 months
and 12 months, survival, clonal evolution to PNH, myelodysplasia and acute leukemia. The
primary endpoint will be changes in absolute neutrophil count, platelet count, and
reticulocyte count at 6 months. Secondary endpoints will include time to relapse, changes in
cytogenetics, and time to death.

Inclusion Criteria


Severe aplastic anemia characterized by:

Bone marrow cellularity less than 30 percent (excluding lymphocytes)


At least two of the following:

Absolute neutrophil count less than 500/ microL

Platelet count less than 20,000/ microL

Absolute reticulocyte count less than 60,000/ microL

Age greater than or equal to 2 years old

Weight greater than or equal to 12 kg


Diagnosis of Fanconi anemia

Cardiac ejection fraction less than 30 percent (evaluated by ECHO)

Evidence of a clonal hematologic bone marrow disorder on cytogenetics. Patients with the
presence of trisomy 8, loss of Y or del(20q) will not be excluded in the absence of
dysplastic changes in the marrow. Patients with very severe neutropenia (ANC less than 200
/microL) will not be excluded initially if cytogenetics are not available or pending. If
evidence of a clonal disorder is later identified, the patient will go off study.

Prior immunosuppressive therapy with high dose Cy or ATG

Infection not adequately controlled with appropriate therapy

Serologic evidence of HIV infection

Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious,
or metabolic disease of such severity that it would preclude the patient's ability to
tolerate protocol therapy, or that death within 30 days is likely

Subjects with cancer who are not considered cured, are on active chemotherapeutic
treatment or who take drugs with hematological effects

Current pregnancy or unwillingness to take oral contraceptives or refrain from pregnancy
if of childbearing potential

Not able to understand the investigational nature of the study or to give informed

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The primary objective is to evaluate the safety and activity profile of Cy/CsA in SAA.

Principal Investigator

Danielle M Townsley, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Heart, Lung, and Blood Institute (NHLBI)


United States: Federal Government

Study ID:




Start Date:

August 2010

Completion Date:

June 2014

Related Keywords:

  • Aplastic Anemia
  • Neutropenia
  • Pancytopenia
  • Severe Aplastic Anemia
  • Aplastic Anemia
  • Immunosuppression
  • T-Cells
  • Hematopoiesis
  • Autoimmunity
  • Severe Aplastic Anemia
  • Anemia
  • Anemia, Aplastic
  • Neutropenia
  • Pancytopenia



National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland  20892